NetworkNewsBreaks – Acer Therapeutics, Inc. (NASDAQ: ACER) Featured in ROTH Equity Research Report
Acer Therapeutics, Inc. (NASDAQ: ACER) was featured in a recent equity research report published by ROTH Capital Partners LLC. The report reads, “With yesterday's update that ACER-001 showed bioequivalence to the already approved Buphenyl for treatment of UCDs, ACER now has green lights ahead of a planned NDA submission for its taste-masked drug in early 2021. With NDA-bound ACER-001 development on the upswing and the FDRR for EDSIVO in review (submitted Dec. 2019), we believe the follow-through on execution has set ACER up for a strong 2020.” To request access to the full report, visit http://nnw.fm/DXCr3 About Acer Therapeutics, Inc.…







